Active Cancer NIHR-supported project Lungs & Breathing

A multi-site, prospective, open-label Phase I/II trial of Actinium (225Ac) rhPSMA 10.1 to evaluate safety and anti-tumour activity in men with metastatic castrate-resistant prostate cancer (mCRPC) who have previously responded to Lutetium-PSMA.

Funder NIHR (part of DHSC)
Recipient organisation NIHR University College London Hospitals Biomedical Research Centre
NIHR support Recorded as supported by this research centre
Period Jan 2025 — Feb 2030

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Gerhardt Attard (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

ACT-RESoLUTE - A multi-site, prospective, open-label Phase I/II trial of Actinium (225Ac) rhPSMA-10.1 to evaluate safety and anti-tumour activity in men with metastatic castrate-resistant prostate cancer (mCRPC) including those who have previously responded to Lutetium-PSMA
PAnTHA - A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac- PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)
A Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of actinium-225-macropa-pelgifatamab (BAY3546828)in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)
An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA10.1 injection in men with metastatic castrate resistant prostate cancer
A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)

Original classification

Cancer

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.